文献速递肝病

恩替卡韦联合聚乙二醇干扰素α-2a治疗成人乙型肝炎e抗原阳性免疫耐受期慢性乙型肝炎病毒感染

Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.
PubMed 文献 · Hepatology · 2019-03-14

研究纳入28例乙型肝炎e抗原阳性、HBV DNA>10^7 IU/mL且ALT≤1.5倍正常上限的成人免疫耐受期慢性乙型肝炎患者,先接受恩替卡韦0.5 mg每日1次治疗8周,随后加用聚乙二醇干扰素α-2a 180 μg/周联合恩替卡韦治疗40周。主要终点为治疗结束后48周时乙型肝炎e抗原消失且HBV DNA≤1,000 IU/mL;结果仅1例(4%)清除乙型肝炎e抗原,无1例达到主要终点,结论认为该方案疗效有限且不能推荐。

要点

  • 28例免疫耐受期成人中仅1例(4%)清除乙型肝炎e抗原,无1例达到主要终点。
  • 8例(29%)出现ALT升高>5倍正常上限,均未伴黄疸。
  • 治疗结束后48周所有患者HBV DNA反弹至基线水平,该方案不能推荐。

核心结论

  • 先导8周恩替卡韦后联合聚乙二醇干扰素和恩替卡韦治疗40周的方案在成人免疫耐受期慢性乙型肝炎患者中疗效有限,不能推荐。

研究设计与样本

  • 研究纳入28例来自11个中心的乙型肝炎e抗原阳性、HBV DNA>10^7 IU/mL且ALT≤1.5倍正常上限(男性≤45 U/L,女性≤30 U/L)的成人免疫耐受期慢性乙型肝炎患者。
  • 患者先接受恩替卡韦0.5 mg每日1次治疗8周,随后加用聚乙二醇干扰素α-2a 180 μg/周联合恩替卡韦治疗40周。
  • 主要终点为治疗结束后48周时乙型肝炎e抗原消失且HBV DNA≤1,000 IU/mL。

主要发现

  • 28例参与者中位年龄37.2岁(范围22-61岁),54%为男性,96%为亚洲人。
  • 基因型C占64%,基因型B占32%;基线HBV DNA中位数8.2 log10 IU/mL,ALT为0.9倍正常上限。
  • 1例(4%)参与者清除乙型肝炎e抗原,但无1例达到主要终点(乙型肝炎e抗原消失且HBV DNA≤1,000 IU/mL)。
  • 8例(29%)参与者出现ALT升高>5倍正常上限,均未伴黄疸。
  • 治疗结束后48周,所有参与者HBV DNA反弹至基线水平(包括乙型肝炎e抗原清除者),除4例参与者外其余ALT恢复至接近基线水平。

临床怎么用

  • 原文结论认为该联合方案在成人免疫耐受期慢性乙型肝炎中疗效有限且不能推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monotherapy with interferon or nucleoside analog is generally not recommended during the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase. Small pediatric studies reported efficacy with combination nucleoside analog and interferon therapy. The aim of this study was to evaluate the safety and efficacy of the combination of entecavir and peginterferon in adults in the IT phase of chronic HBV infection. Hepatitis B e antigen (HBeAg)-positive adults with HBV DNA > 107 IU/mL and alanine aminotransferase (ALT) ≤ 1.5 times the upper limit of normal (ULN) (male: ≤ 45, female: ≤ 30 U/L) received entecavir 0.5 mg daily for 8 weeks followed by the addition of peginterferon alfa-2a 180 µg/week to entecavir for an additional 40 weeks. The primary endpoint was HBeAg loss and HBV DNA ≤ 1,000 IU/mL 48 weeks after end of treatment (EOT). Among 28 participants from 11 sites, the median age was 37.2 (range: 22-61) years, 54% were male, and 96% were Asian. Nearly all were infected with genotype C (64%) or B (32%). Median baseline HBV DNA was 8.2 log10 IU/mL, and ALT was 0.9 times the ULN. Although one (4%) participant cleared HBeAg, none met the primary endpoint of both HBeAg loss AND HBV DNA ≤ 1,000 IU/mL 48 weeks post-EOT. ALT elevations > 5 times the ULN occurred in eight (29%) participants, and none were associated with icterus. Forty-eight weeks posttreatment, HBV DNA rebounded to baseline levels in all participants, including the participant who lost HBeAg, and ALT values returned to near baseline levels in all but four participants. Conclusion: A lead-in strategy of 8 weeks of entecavir followed by combination peginterferon and entecavir therapy for 40 weeks had limited efficacy in adults in the IT phase of chronic HBV infection and cannot be recommended.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Feld JJ, Terrault NA, Lin HS, et al. Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. Hepatology. 2019. PMID: 30549279. doi:10.1002/hep.30417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。